iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) enrolled the first patients in its GALACTIC registry to evaluate GraftAssure for monitoring rejection in kidney transplant recipients. The first samples arrived in Tennessee from UCLA Medical Center. The 5,000-participant observational study spans multiple centers and has a planned follow-up of about three years.
The registry targets a positive predictive value above 80%, versus roughly 50% for current tests, the company said. That measure is the share of positive results that correctly identify rejection. The study will assess whether the test can guide biopsy and anti-rejection medication decisions and will track long-term outcomes.
iMDx expects the registry to give more transplant centers experience with GraftAssure while the GraftAssureDx kit remains under FDA review.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointFirst GALACTIC enrollments began at UCLA Medical Center, with initial patient samples received in Tennessee
- Minor point. Forward-looking: it has not happened yet and may not happen.GALACTIC validation study is designed for 5,000 participants, with a planned follow-up of about three years
- Minor point. Forward-looking: it has not happened yet and may not happen.GALACTIC performance target is positive predictive value above 80%, versus roughly 50% for current assays, iMDx said
- Minor pointPrior peer-reviewed CM-Score study showed 81% positive predictive value versus a 54% published single-measure benchmark, and 91% negative predictive value
- Minor point. Forward-looking: it has not happened yet and may not happen.Transplant center engagement has a multi-year iMDx target of 50 U.S. centers to evaluate the combined score
- Minor point. Forward-looking: it has not happened yet and may not happen.Registry evidence is expected by iMDx to support future payer coverage decisions for GraftAssure products
Negative
- Moderate pointGraftAssureDx FDA authorization remains pending, with the kit under review for use in clinical decision-making
News Explained
The registry is also intended to bridge findings from GraftAssureCore, run in iMDx’s CLIA lab, to GraftAssureDx, a kit in development for in-house use at transplant centers.
Key Figures
- Registry size
- 5,000 participants
- GALACTIC multi-center registry study
- Planned follow-up
- ~3 years
- GALACTIC registry study
- Target positive predictive value
- above 80%
- GALACTIC study aim
- Current-assay positive predictive value
- roughly 50%
- Comparator stated for the GALACTIC study aim
- Positive predictive value
- 81%
- Previously published CM-Score study
- Single-metric dd-cfDNA benchmark
- 54%
- Published benchmark cited alongside prior CM-Score results
- Negative predictive value
- 91%
- Previously published CM-Score study
Historical Context
-
FDA preliminary view said submitted clinical data did not yet support the proposed intended use.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
positive predictive value medical
dd-cfDNA medical
digital pcr technical
clia regulatory
in vitro diagnostic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Patient samples arrive in Tennessee from UCLA Medical Center, officially kicking off 5,000-participant, multi-center novel registry first announced September 2025
- Registry program is designed to be incremental, complementary, and symbiotic to iMDx “kitted strategy” and allow clinical community to gain experience using GraftAssure testing technology
- Study involvement expected to expand access to GraftAssure technology ahead of potential FDA authorization of a kitted form of the clinical assay, currently under review
NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC (GraftAssure Lowering Allograft rejeCTIon by Combination) registry study, a prospective, multi-center validation study evaluating GraftAssureTM, the company's molecular test for monitoring rejection in kidney transplant recipients.
This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.
“Here at UCLA, we are always interested in innovative research and therefore, we are participating in the GALACTIC Registry, offered by iMDx,” said UCLA Medical Center’s Dr. Suphamai (Michael) Bunnapradist, MD, MS. “Through this registry we will be able to monitor our patients’ transplanted kidney health, initially with a send-out test and ultimately through in-house testing. It is also very exciting to be the center that enrolled the first patient into this national registry.”
iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated
“We are excited to enroll our first patients in the GALACTIC registry study, the goal of which is to gather performance metrics on GraftAssure to guide biopsy and treatment decisions and congratulations to the UCLA team on enrolling the first participants. UCLA played a foundational role in validating donor-derived cell-free DNA for transplant monitoring, and we are pleased to have them help answer an important clinical question: ‘Can GraftAssure better identify patients whose biopsies will confirm rejection?’” iMDx CEO Josh Riggs said. “GALACTIC aims to demonstrate a positive predictive value above
Mr. Riggs continued, “We expect that the data from this registry is what payers and clinicians will look to for real-world evidence, and that it will support payer coverage decisions down the line for the family of products using GraftAssure technology.”
About the GALACTIC Registry Study
The GALACTIC registry study is designed as an observational study of iMDx’s GraftAssure clinical assay in kidney transplant patients to build evidence supporting the previously published Combination Model (CM)-Score and relate it to real-world outcomes.
Additionally, iMDx expects that the study will bridge findings directly from its CLIA lab-run GraftAssureCore test to its GraftAssureDx kitted test in development to be run in-house within transplant centers. The study also has a planned ~3-year follow-up period.
About the CM-Score Used with GraftAssure Technology
Through the launch of its study, iMDx is making progress toward driving clinical adoption and building a scientific case for why digital PCR, which is natively quantitative, can enable use cases for dd-cfDNA testing beyond what is currently on the market. To that end, iMDx established a multi-year target of engaging with 50 U.S. transplant centers to evaluate the clinical utility of its combined score.
This combined score, or CM-score, uses two independent measurements of dd-cfDNA, which the company believes improves the clinical performance of dd-cfDNA compared to currently available options. Specifically, the CM-score mathematically combines the relative (percentage, or %) and absolute (copies per milliliter, or cp/mL) measurements of DNA fragments from the transplanted organ, which in this case is the kidney. This data was first presented as late breaking at the World Transplant Congress in August 2025.
In a peer-reviewed study published in the American Journal of Transplantation in June 2026, and as highlighted in a press release issued the same month, the CM-Score demonstrated a positive predictive value of
The GALACTIC registry is intended to confirm these findings prospectively in real-world clinical use, evaluate their impact on biopsy and immunosuppression management decisions, and generate long-term outcome data. Collection of these data points is intended to support validation as GraftAssure access is expected to expand to new transplant centers upon planned commercialization.
iMDx Transplant Products and Product Candidates in Development
iMDx’s flagship transplant testing technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The Company’s scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. iMDx is commercializing this technology using a market-disruptive business strategy. Under the GraftAssure™ brand, iMDx’s transplant diagnostics include the following:
- GraftAssureCore – The company’s laboratory-developed test (LDT), currently reimbursed by CMS MolDX at
$2,753 per result and performed at iMDx’s CLIA-certified laboratory in Franklin, Tennessee. - GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for non-clinical applications.
- GraftAssureDx – The in vitro diagnostic (IVD) kit currently under FDA review for use in clinical decision-making.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Forward-Looking Statements
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, expected FDA marketing authorization to sell GraftAssureDx, the GALACTIC Registry (including continued enrollment and anticipated data and results) the company’s goals to seek a best-in-class molecular diagnostics test kit to expand and improve testing access for kidney transplant patients and deliver new value in the estimated
Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
FDA
CAUTION: This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.
Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.